Dasatinib

2-Deoxy-D-glucose (2-DG) and BPTES were purchased from Sigma-Aldrich. JQ1 and dasatinib were purchased from Apexbio Technology (Houston, TX). BS-181 was purchased from MedChem Express (Monmouth Junction, NJ). All other inhibitors were purchased from Selleck Chemicals (Houston, TX). For stock preparations, see Extended Experimental Methods.

Cells were seeded at 2,500 cells per well of 96-well plates 24 hours prior to treatments. To generate GI₅₀ curves, cells were treated with vehicle (DMSO) or serial dilutions of each drug for 72 hours. Each treatment condition was completed in technical triplicate. Cell viability was read-out using CellTiter Glo (Promega G7573) on a BioTek Synergy2 plate reader. The total number of live cells for each drug dose were normalized to the vehicle control and GI₅₀ drug curves were established using GraphPad Prism. For combinations, one drug was added at a constant concentration across all wells and total live cell counts were normalized to the secondary drug-only condition. For three-day growth curves, cells were seeded at 2,500 cells per well of 96-well plates 24 hours prior to treatment and treated with stable concentrations of each drug. Total live cell counts were measured using CellTiter Glo on each day, and relative luciferase units were plotted to represent cell growth over time. Drugs used include BYL719 (Selleckchem S2814) and A-1331852 (Chemietek 1430844–80-6), PIM447 (Selleckchem S7985) and Dasatinib (ApexBio A3017).